MA50038A - Anticorps anti-pd-l1 de et son utilisation - Google Patents
Anticorps anti-pd-l1 de et son utilisationInfo
- Publication number
- MA50038A MA50038A MA050038A MA50038A MA50038A MA 50038 A MA50038 A MA 50038A MA 050038 A MA050038 A MA 050038A MA 50038 A MA50038 A MA 50038A MA 50038 A MA50038 A MA 50038A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2017028206 | 2017-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50038A true MA50038A (fr) | 2020-07-08 |
Family
ID=63856823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050038A MA50038A (fr) | 2017-04-18 | 2018-04-18 | Anticorps anti-pd-l1 de et son utilisation |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210115143A1 (fr) |
EP (1) | EP3612565A4 (fr) |
JP (2) | JP2020517239A (fr) |
KR (1) | KR102323960B1 (fr) |
CN (1) | CN110856446A (fr) |
AU (1) | AU2018256392B2 (fr) |
BR (1) | BR112019021828B1 (fr) |
CA (1) | CA3059447A1 (fr) |
CL (1) | CL2019002953A1 (fr) |
CO (1) | CO2019012118A2 (fr) |
EA (1) | EA201900443A1 (fr) |
MA (1) | MA50038A (fr) |
MX (1) | MX2019012461A (fr) |
PH (1) | PH12019502302A1 (fr) |
SG (1) | SG11201909041SA (fr) |
WO (1) | WO2018195226A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
EP3534947A1 (fr) | 2016-11-03 | 2019-09-11 | Kymab Limited | Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés |
CN113646330A (zh) * | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术(上海)有限公司 | 针对程序性死亡配体的结合物及其应用 |
WO2020209645A1 (fr) * | 2019-04-11 | 2020-10-15 | (재) 스크립스코리아항체연구원 | Anticorps dirigé contre le ligand 1 de la protéine de mort cellulaire programmée (pd-l1), et son utilisation |
CA3112681A1 (fr) * | 2019-04-26 | 2020-10-29 | I-Mab Biopharma Us Limited | Anticorps anti-pd-l1 humains |
US20210403568A1 (en) * | 2020-06-29 | 2021-12-30 | Cai Gu Huang | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
UA109108C2 (uk) * | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
US10202454B2 (en) * | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
KR102395498B1 (ko) * | 2014-01-06 | 2022-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
US9688754B2 (en) * | 2014-02-20 | 2017-06-27 | Alder Biopharmaceuticals, Inc. | Anti-ACTH antibodies and use thereof |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
MX2017011644A (es) * | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
WO2018080812A1 (fr) * | 2016-10-30 | 2018-05-03 | Henlix, Inc. | Anticorps anti-pd-l1 et variants |
-
2018
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/fr active Pending
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en active Active
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko active IP Right Grant
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/fr unknown
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 CA CA3059447A patent/CA3059447A1/fr active Pending
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt active IP Right Grant
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110856446A (zh) | 2020-02-28 |
BR112019021828B1 (pt) | 2022-09-20 |
BR112019021828A2 (pt) | 2020-03-24 |
CA3059447A1 (fr) | 2018-10-25 |
KR102323960B1 (ko) | 2021-11-10 |
EA201900443A1 (ru) | 2020-03-06 |
EP3612565A1 (fr) | 2020-02-26 |
AU2018256392A1 (en) | 2019-10-17 |
SG11201909041SA (en) | 2019-11-28 |
KR20190141169A (ko) | 2019-12-23 |
JP2023025003A (ja) | 2023-02-21 |
JP2020517239A (ja) | 2020-06-18 |
AU2018256392B2 (en) | 2024-05-16 |
CL2019002953A1 (es) | 2020-01-10 |
EP3612565A4 (fr) | 2021-06-16 |
CO2019012118A2 (es) | 2020-04-01 |
MX2019012461A (es) | 2019-12-11 |
WO2018195226A1 (fr) | 2018-10-25 |
US20210115143A1 (en) | 2021-04-22 |
PH12019502302A1 (en) | 2020-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
MA47694A (fr) | Anticorps anti-tigit | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA50038A (fr) | Anticorps anti-pd-l1 de et son utilisation | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
MA47268A (fr) | Anticorps anti-gpc3 | |
MA53434A (fr) | Anticorps anti-tigit | |
IL273411A (en) | Antibody against PD-L1 and its uses | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA46057A (fr) | Anticorps anti-ctla4 | |
MA52884A (fr) | Anticorps anti-il-11 | |
DK3455257T3 (da) | Anti-pd-l1-antistoffer | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA47311A (fr) | Anticorps anti-tgf-bêta et leur utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA52284A (fr) | Anticorps anti-hla-g et leur utilisation | |
MA49749A (fr) | Anticorps anti-cd137 | |
ES2969440T3 (es) | Anticuerpos anti-C5 y métodos de uso | |
MA52285A (fr) | Anticorps multispécifiques et leur utilisation |